Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q1 FY2024 Earnings Presentation
30 slides from Jubilant Ingrevia's earnings presentation, Jul 26, 2023
Slide 1: Investor Presentation
Investor Presentation July 2023 Jubilant Ingrevia Limited 1
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Table of Contents
Company Snapshot - 04 Financial Highlights – Q1 FY’23 - 08 Business Segments Overview - 12 Business Enablers Snapshot - 22 Table of Contents 3
Slide 4: Company Overview
Company Overview Jubilant Ingrevia Limited 4
Slide 5: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod
Slide 6: Company Snapshot
Company Snapshot Q1’FY24 | Rs. 1,075 Cr Q1’FY24 | Rs. 125 Cr Q1’FY24 | Rs. 58 Cr FY23 | Rs. 4,773 Cr FY23 | Rs. 580 Cr FY23 | Rs. 308 Cr Revenue EBITDA PAT Expertise in 35 technology 134+ platforms and multistep Catering to 1500+ customers products commercialized across business segments chemistry 6
Slide 7: Integrated Business Segments
Integrated Business Segments Jubilant Ingrevia Limited Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates • Pyridine & Picolines • Acetyls • Nutrition & Health Ingredients • Fine Chemicals • Specialty Ethanol • Agro Chemicals • Animal & Human Nutrition Health Solutions • CDMO Mo
Slide 8: Financial Highlights Q1 FY'24
Financial Highlights Q1 FY’24 8
Slide 9: Chairmen's Message on Q1'FY24 Financial Results
Chairmen’s Message on Q1’FY24 Financial Results- Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are pleased to announce stable performance in Q1’FY24, given the backdrop of depressed market conditions specifically in Agrochemical end use markets. In our Specialty Chemicals Business,
Slide 10: Financial Results Overview | Consolidated
Financial Results Overview | Consolidated Particulars1 Q1'FY23 Q4'FY23 Q1'FY24 Q-o-Q Y-o-Y Total Revenue 1,166 1,145 1,075 -6% -8% Total EBITDA 151 111 125 13% -17% EBITDA Margin (%) 12.9% 9.7% 11.6% Profit After Tax 79 52 58 10% -27% Profit After Tax Margin (%) 6.8% 4.6% 5.4% Basic and Diluted EPS
Slide 11: Key Ratios | As on 30th June 2023
Key Ratios| As on 30th June 2023 1 Particulars FY’2023 Q1'FY2024 Net Debt 312 492 Net Debt to Equity 0.12x 0.18x Net Debt to EBITDA 0.54x 0.89x Working Captal to Turnover 17% 20% 1. All figures are in Rs Crore unless otherwise stated 11
Slide 12: Business Segments Overview
Business Segments Overview 12
Slide 13: Financials | Speciality Chemicals Segment
Financials | Speciality Chemicals Segment Particulars1 Q1'FY23 Q4'FY23 Q1'FY24 Q-o-Q Y-o-Y Segment Revenues 382 468 364 -22% -5% % Contribution to Revenues 33% 41% 34% EBITDA 64 55 57 3% -11% % EBITDA Margins 17% 12% 16% % Contribution to EBITDA 43% 50% 46% 1. All figures are in Rs Crore unless othe
Slide 14: Business Highlights | Speciality Chemicals Segment
Business Highlights | Speciality Chemicals Segment • Registered growth in volumes of Specialty products towards non-agrochemical end-use including CDMO, resulting into normalization and sequential margins improvement of overall segments. • Demand from customers from Agrochemical end use continue to
Slide 15: Business Segment Overview | Speciality Chemicals
Business Segment Overview | Speciality Chemicals 70+ Products (Pyridines & Picolines, Globally among Top 2 Globally lowest cost Serving 15 of top 20 Cyanopyridines, in (Pyridine+Beta); producer of Pyridine Global Pharma & 7 of Piperidines, Globally #1 in 18 offering significant top 10 Global Aminopy
Slide 16: Financial Highlights | Nutrition & Health Solutions
Financial Highlights |Nutrition & Health Solutions 1 Particulars Q1'FY23 Q4'FY23 Q1'FY24 Q-o-Q Y-o-Y Segment Revenues 150 155 202 30% 35% % Contribution to Revenues 13% 14% 19% EBITDA 19 5 17 246% -10% % EBITDA Margins 13% 3% 8% % Contribution to EBITDA 12% 4% 13% 1. All figures are in Rs Crore unle
Slide 17: Business Highlights | Nutrition & Health Solutions
Business Highlights |Nutrition & Health Solutions • Our Nutrition & Health Ingredients (NHI) business registered significant improvement in Niacinamide volumes. We continue to see improvement in Price realisation of Niacinamide globally. • NHI Business continues to focus on improving volumes and sha
Slide 18: Business Segment Overview | Nutrition & Health Solutions
Business Segment Overview | Nutrition & Health Solutions Catering to Varied End Use Industries, ranging from, Personal 5 Nutrition Ingredients Care, Pharmaceuticals and Animal Feed & Global top 2 in Full Backward 18+ branded solutions Vitamin B3 Integration for Vitamin B3 via green Niainamide End Us
Slide 19: Financial Highlights | Chemical Intermediates
Financial Highlights | Chemical Intermediates 1 Particulars Q1'FY23 Q4'FY23 Q1'FY24 Q-o-Q Y-o-Y Segment Revenues 633 522 509 -2% -20% % Contribution to Revenues 54% 46% 47% EBITDA 76 59 60 2% -22% % EBITDA Margins 12% 11% 12% % Contribution to EBITDA 51% 53% 48% 1. All figures are in Rs Crore unless
Slide 20: Business Highlights | Chemical Intermediates
Business Highlights | Chemical Intermediates • Newly commissioned Acetic Anhydride plant at Bharuch is ramping up as expected. • Business continues to improve its market share of Acetic Anhydride in domestic as well as International market. • The Price realizations of Acetic Anhydride witnessed head
Slide 21: Business Segment Overview | Chemical Intermediates
Business Segment Overview | Chemical Intermediates Catering to Varied End Use Industries, most of these end use 9 Products having promising growth Acetic Anhydride: (Acetic Anhydride, Ethyl Globally No. 2 in Acetate ,Propionic Merchant Mkt Anhydride, Aldehydes, No.1 in India Speciality Alcohol, Esti
Slide 22: Business Enablers
Business Enablers Jubilant Ingrevia Limited 22
Slide 23: Key Technology Platforms
Research Development & Technology (RDT) Key Highlights 35 Key technology platforms developed & commercialized to global standards. Some 3 RDT centers in Noida, Gajraula and are unique: Ammoxidation, Grignard etc. Bharuch 120 highly qualified scientists (21 PhDs) 33 Products in Pipeline for next 4 ye
Slide 24: Multi Location Manufacturing & Operation Excellence
Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India India Speciality Chemicals, Integrated facility for Nutrition & Health Samlaya, Gujarat, India Ambernath, Maharashtra, Speci
Slide 25: Sustainability
Sustainability First time participated in S&P DJSI Assessment: Bharuch Nira Gajraula Global chemical industry's EHS initiative (Dec (Oct (Oct & Ethical framework towards safe chemicals • Achieved 95 percentile in the 2018) 2019) 2021) management and performance excellence Global Chemical Industry •
Slide 26: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships
Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships Mission: To develop multi-stakeholder sustainable models to 1 Aspiring to touch the Lives Established Million bring about ‘social change’ involving knowledge generation through social initiatives in 2007 lives & sharing, ex
Slide 27: Annexure 1- Income Statement | Consolidated
Annexure 1- Income Statement | Consolidated Particulars1 Q1'FY23 Q4'FY23 Q1'FY24 QoQ YoY Revenue from operations a) Sales/Income from operations 1159 1129 1069 -5% -8% b) Other operating income 6 16 6 -59% -1% Total revenue from operations 1166 1145 1075 -6% -8% Other income 10 9 9 -6% -16% Total in
Slide 28: Annexure II: Income Statement Segmental – Q1'FY24
Annexure II: Income Statement Segmental – Q1‘FY24 1 Particulars Q1'FY23 Q4'FY23 Q1'FY24 QoQ (%) YoY (%) Total Revenue from Operations 1,166 1,145 1,075 (6%) (8%) Speciality Chemicals 382 468 364 (22%) (5%) Nutrition & Health Solutions 150 155 202 30% 35% Chemical Intermediates 633 522 509 (2%) (20%)
Slide 29: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Jubilant Ingrevia Limited. Industrial customers with customised products and solut
Slide 30: Annexure III - Conference Call Details
Annexure III - Conference Call Details Diamond Pass Log-In Date : July 27th, 2023 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, pass